Mirikizumab is a Monoclonal Antibody owned by Eli Lilly and Co, and is involved in 30 clinical trials, of which 22 were completed, 7 are ongoing, and 1 is planned.

Mirikizumab is an anti-IL-23p19 humanized antibody. IL-23 is a key tissue-specific effector cytokine that amplifies the inflammatory response and is over-expressed in psoriatic lesions. It binds to p19 subunit and neutralizes human interleukin IL-23 mediated cellular responses. IL-23 mediates inflammatory responses by production of IFN-gamma (interferon gamma). The drug candidate targets these highly expressed IL-23 cytokines.

The revenue for Mirikizumab is expected to reach a total of $14.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Mirikizumab NPV Report.

Mirikizumab is originated and owned by Eli Lilly and Co.

Mirikizumab Overview

Mirikizumab is under development for the treatment of Crohn's disease and moderate to severe ulcerative colitis in adults and pediatric patients. It is administered intravenously or subcutaneously. It is a humanized antibody that targets p19 subunit of interleukin-23. The drug candidate is a new biological entity (NBE). It was under development of moderate to severe plaque psoriasis.

Eli Lilly and Co Overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

The company reported revenues of (US Dollars) US$28,318.4 million for the fiscal year ended December 2021 (FY2021), an increase of 15.4% over FY2020. In FY2021, the company’s operating margin was 21%, compared to an operating margin of 24.7% in FY2020. In FY2021, the company recorded a net margin of 19.7%, compared to a net margin of 25.2% in FY2020. The company reported revenues of US$6,941.6 million for the third quarter ended September 2022, an increase of 7% over the previous quarter.

Quick View – Mirikizumab

Report Segments
  • Innovator
Drug Name
  • Mirikizumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Immunology
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.